Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Search
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Manufacturing & Supply Chain
Manufacturing & Supply Chain
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Brazil
Brazil
Dubai
Dubai
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Information Technology
IT
Human Health Partnering
Human Health Partnering
Parasiticides
Parasiticides
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
From garbage to garden - Recycling organic waste to contribute to a healthier planet
From garbage to garden - Recycling organic waste to contribute to a healthier planet
Technologies
We are expanding our global network of technology partners. Learn more about partnering with us.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Mental Health disorders
Mental Health disorders
We’re All In
We’re All In
Animal Health Partnering
Animal Health Partnering
Vaccines
Vaccines
A grandmother’s empathy offers a safe space for people with mental health conditions
Supporting the Friendship Bench to improve access to mental healthcare.
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Metabolic Diseases
CardioMetabolic Disease Research
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Citizen Petition
Citizen Petition
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health